Description
Product Description
Infliximab is a recombinant chimeric IgG1 monoclonal antibody composed of human constant regions and murine variable regions that specifically recognize and neutralize tumor necrosis factor-alpha (TNF-α). TNF-α is a key pro-inflammatory cytokine involved in immune regulation, apoptosis, and inflammatory signaling pathways.
In preclinical research, infliximab is employed to investigate:
TNF-α mediated signaling pathways.
Cytokine network regulation and inflammatory responses.
Cellular and molecular mechanisms of immune modulation.
Potential therapeutic strategies in models of autoimmune and inflammatory diseases.
Structurally, infliximab binds with high affinity to both soluble and transmembrane forms of TNF-α, preventing it from interacting with TNF receptors (TNFR1 and TNFR2) on target cells. This blockade inhibits downstream NF-κB activation, MAPK signaling, and pro-inflammatory cytokine production, providing a valuable tool for mechanistic studies of immune response and inflammation.
Researchers often utilize infliximab in vitro and in vivo to model TNF-dependent processes, evaluate combination strategies with other cytokine modulators, and study resistance or compensatory immune pathways. Its chimeric nature allows preclinical exploration of monoclonal antibody pharmacokinetics, receptor binding kinetics, and immune effector functions such as antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) in experimental models.
Product Specifications
| Item | Specification |
|---|---|
| Product Name | Infliximab |
| CAS Number | 170277-31-3 |
| Synonyms | Anti-TNFα mAb; Remicade® (research grade) |
| Molecular Formula | Not applicable (protein) |
| Molecular Weight | ~149 kDa |
| Purity | ≥99% (protein-based assay) |
| Appearance | Lyophilized white to off-white powder |
| Solubility | Soluble in sterile PBS or suitable buffer for cell culture |
| Storage Temperature | 2–8 °C, avoid repeated freeze-thaw |
| Category | Monoclonal antibody, immunology research reagent |
| Applications | TNF-α signaling studies, immune modulation research, cytokine pathway analysis, inflammatory disease modeling |
| Formulation | Lyophilized powder, suitable for in vitro and ex vivo experiments |
| Stability | Stable under recommended storage conditions |
| Shelf Life | 12–24 months (research-grade preparation) |
| Supplier Type | Research-grade antibody supplier |
| Intended Use | For laboratory research use only |
Mechanism of Action
Infliximab functions as a chimeric monoclonal antibody that neutralizes TNF-α, preventing it from binding to its receptors TNFR1 and TNFR2.
1. TNF-α Neutralization
Infliximab binds with high specificity to soluble and membrane-bound TNF-α, inhibiting its interaction with TNF receptors on target cells. This blockade reduces pro-inflammatory signaling cascades and downstream gene transcription.
2. Inhibition of Pro-Inflammatory Signaling
By preventing TNF-α receptor activation, infliximab suppresses the NF-κB pathway, MAP kinase activation, and production of inflammatory cytokines such as IL-1, IL-6, and IL-8.
3. Modulation of Immune Cells
Infliximab can influence macrophage, dendritic cell, and T-cell responses in vitro, modulating immune activation, apoptosis, and cytokine secretion in TNF-dependent experimental models.
4. Research Applications
Studying the role of TNF-α in autoimmune and inflammatory disease models.
Evaluating cytokine-targeted strategies in preclinical immunology research.
Investigating combination studies with other immune modulators or anti-inflammatory compounds.
Assessing antibody-mediated effector functions (ADCC, CDC) in experimental cell lines.

Infliximab
Side Effects
In laboratory studies, infliximab is generally well-tolerated in controlled experimental conditions. Potential laboratory observations may include:
Modulation of cytokine secretion and immune cell activation.
Altered cell viability in TNF-dependent assays at high concentrations.
Effects on apoptosis and proliferation in TNF-responsive cell lines.
These effects are purely experimental. Infliximab is not intended for human or veterinary administration. Proper biosafety and handling procedures are required.
Keywords
Infliximab, CAS 170277-31-3, anti-TNFα antibody, monoclonal antibody research, immunology reagent, cytokine signaling inhibitor, inflammatory pathway research, chimeric mAb, high-purity antibody, research antibody supplier, OEM & bulk antibody production China.
Shipping Guarantee
All shipments are handled using validated cold-chain logistics to preserve protein integrity. Each package is sealed in moisture-proof containers with secondary protective wrapping and continuous temperature monitoring. Products are shipped via express international couriers with full tracking and insurance coverage.
Trade Assurance
We ensure product authenticity, verified ≥99% purity, and compliance with analytical protein assays. Each batch is supplied with a Certificate of Analysis (CoA). Our trade assurance policy guarantees replacement or refund for any deviation from listed specifications.
Payment Support
We provide flexible and secure global payment options to support international research transactions. Accepted payment methods include PayPal, major credit cards (Visa, MasterCard, American Express), telegraphic transfer (T/T), and cryptocurrencies (USDT, Bitcoin, Ethereum). All transactions are protected by industry-standard encryption and verified payment gateways to ensure confidentiality and fund security.
Disclaimer
All products listed are intended for laboratory research use only and not for human or veterinary use. They are not drugs, medical devices, or diagnostics and should not be administered to humans or animals. Researchers must handle all materials in accordance with institutional biosafety and chemical safety guidelines. The information provided is for scientific reference only and does not imply therapeutic efficacy, safety, or regulatory approval.




Reviews
There are no reviews yet.